Eger, Stephan; Mahlich, Jörg C. - In: Health economics review 4 (2014) 23, pp. 1-9
companies between 2000 and 2008. The share of sales in Europe serves as a proxy for the degree of pharmaceutical regulation. We …'s q. Results: Our results suggest a nonlinear relationship between European sales ratio and R&D intensity. Beyond a … threshold of 33% of sales generated in Europe, a higher presence in Europe is associated with lower R&D investments. Conclusion …